



Published: June 30, 2024

Citation: Raghavan PR., 2024. Metadichol®-induced expression of circadian clock transcription factors in human fibroblasts, Medical Research Archives, [online] 12(6). <https://doi.org/10.18103/mra.v12i6.5371>

Copyright: © 2024 European Society of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI

<https://doi.org/10.18103/mra.v12i6.5371>

ISSN: 2375-1924

RESEARCH ARTICLE

Metadichol®-induced expression of circadian clock transcription factors in human fibroblasts

P.R. Raghavan

Nanorx, Inc., PO Box 131, Chappaqua, NY 10514, USA

Email: raghavan@nanorxinc.com

ABSTRACT

Circadian clock genes regulate many physiological processes, including sleep, metabolism, inflammation, and cancer. Disruptions in these cycles are associated with heightened vulnerability to cancer, psychiatric diseases, and neurological problems. Circadian clock genes play a vital role in the growth and progression of cancer. Manipulating the circadian clock mechanism can eliminate cancer cells, augment the effectiveness of chemotherapy, eliminate senescent cells, and reinstate regular circadian cycles.

The circadian clock genes that are crucial for regulating the daily physiological processes of mammals include *Cry1*, *Bmal1*, *Per1*, *Ppargc1a*, and *Clock*. Currently, there is a lack of information regarding small molecules that can effectively control and activate all five transcription factors. By subjecting fibroblasts to treatment with Metadichol, we can induce the expression of all the genes, as evidenced by the results obtained from quantitative real-time polymerase chain reaction (qRT-PCR). The administration of metadichol significantly enhanced the expression of the *Cry1*, *Clock*, and *Ppargc1a* genes in human fibroblasts, resulting in a four- to fivefold increase in expression. Metadichol successfully maintained the expression of the *Per1* and *Bmal1* genes at a dose of 100 ng. *Clock* and *Bmal1* heterodimers initiate the activation of *Cry1*, *Per1*, and other clock genes via a feedback loop. The *Cry1* and *Per1* proteins inhibit the function of *Clock*-*Bmal1*. *Ppargc1a* regulates the expression of *Clock* and metabolic genes. Metadichol did not result in elevated levels of *Per1* and *Bmal1* expression, suggesting that it does not directly affect these genes. Metadichol is a nontoxic molecule, and its effects on circadian rhythm can have significant implications for human health to alleviate the progression of numerous ailments and diseases

Keywords: Circadian rhythm, *Clock*, *Bmal1*, *Per1*, *Cry1*, *Ppargc1a*, *NR1D1*, Metadichol, Nanoemulsion, Long-Chain Alcohols, *Sirt 1* and *Sirt 6*.

Introduction

The circadian rhythm is a 24-hour cycle, and it forms the basis for key physiological activities that occur in mammals and are necessary for maintaining equilibrium and health, as well as regulating sleep and wakefulness.^{1,2}

To generate oscillations over a period of twenty-four hours, the biological clock is formed by proteins that are encoded by clock genes. These proteins turn on and off in a specific sequence.¹ All of the biological clocks in the body are controlled by the suprachiasmatic nucleus (SCN) of the brain, which is responsible for synchronizing them to exposure to light and darkness.² This synchronization is essential for determining the timing of actions involving metabolism, the immune system, and hormones.

Through both positive and negative feedback loops, transcription factors are responsible for regulating circadian rhythms at the molecular level. Furthermore, clock genes, including *Bmal1* (basic helix-loop-helix ARNT like 1), *Clock* (clock circadian regulator), *Cry* (cryptochrome circadian regulator 1), *Per1* (period circadian regulator 1) and *Ppargc1a* (PPARG coactivator 1 alpha), are responsible for the regulation of this system. By regulating the pathways that are involved in cellular signaling, these core clock genes influence a number of physiological activities.

Circadian rhythm abnormalities such as a lack of sleep or a misalignment of the circadian rhythm result in several diseases, such as cancer, diabetes, mental health issues, cardiovascular disease, and obesity.³ The *Clock-Bmal1* complex regulates gene expression as well as circadian rhythms while also having an impact on a significant portion of the genome. In cancer, these genes regulate the cell cycle, metabolism, and DNA repair, all of which are significant.⁴

Through a negative feedback loop, *Per1* and *Cry1* contribute to the stability and output of the circadian clock, which is a necessary component of cell cycle control. Their expression influences the timing of the cell cycle as well as the proliferation and development of cancer cells.⁵

One of the transcriptional coactivators known as *Ppargc1a* also called *PGC-1α* is responsible for regulating genes related to energy metabolism through its interaction with the circadian clock. Cancer cells exhibit metabolic defects, and the expression of *Ppargc1a* can mitigate these defects.

⁶

Circadian gene mutations or aberrant expression are linked to several different types of cancer and based on their ability to influence the occurrence of cancer, its growth, and the way it reacts to treatment, they are targets for cancer therapy. Understanding the patterns of expression of these genes could lead to the synchronization of cancer treatments with the circadian clock of the body, improving the effectiveness of treatments and minimizing adverse effects.⁸

Researchers in model organisms that have biological clock genes that are comparable to those found in humans have been able to better understand how circadian rhythms influence both health and illness.⁹ Circadian transcription factor dysregulation leads to epilepsy.¹⁰ It is possible that deregulation of circadian genes could result in mood disorders.^{11,12} This list contains minute substances that influence the genes that control the circadian clock. The clock genes *Per1* and *Bmal1* are regulated by resveratrol, a naturally occurring polyphenol, in rat-1 fibroblasts; however, this is not the case in human cells.¹³ Resveratrol has numerous health benefits, such as antiaging, anticancer, and anti-inflammatory effects. Additionally, resveratrol modulates metabolism and the circadian clock through the mechanisms of *Sirt1* and *PGC-1α*.

Cry proteins are activated by the synthetic small molecule KLO01, which stabilizes and blocks the degradation of these proteins by the ubiquitin-proteasome system. Glucagon suppresses primary hepatocyte gluconeogenesis, which increases the duration of the circadian period.^{14,15} KLO01 blocks this process. It has been demonstrated that KLO01 has antidiabetic effects in mouse models of type 2 diabetes.

The synthetic small molecule SR9009 can bind and activate the nuclear receptor *REV-ERBα* (*NR1D1*), hence suppressing the production of *Bmal1* and clock genes. SR9009 has been shown to affect the circadian rhythm and metabolism of mice, which offers the possibility that it could be used to treat obesity, diabetes, and sleep disorders.¹⁶

Thus, circadian rhythm transcription factors are integral to the proper functioning of the biological clock and, by extension, to human health. These proteins regulate the timing of various biological processes, and their disruption can lead to a plethora of health issues. Herein, we show for the first time that Metadichol¹⁷, a lipid emulsion of long-chain alcohols, can express all these factors and could serve as the basis for overcoming defects

in the circadian rhythm necessary for maintaining whole-body homeostasis.

EXPERIMENTAL

All experiments were designed and outsourced to the commercial service provider Skanda Biolabs Ltd., Bangalore, India. The pathway Studio was outsourced on commercial terms to Elsevier R&D Solutions, Inc. 18 The raw data are provided in the Supplemental files.

CELL TREATMENT

The cells were treated for 24 hours at the indicated concentrations (1 pg, 100 pg, 1 ng and 100 ng/ml) of growth media without FBS (fetal bovine serum).

SAMPLE PREPARATION AND RNA ISOLATION

The treated cells were harvested, rinsed with sterile 1X PBS, and centrifuged. The supernatant was decanted, and 0.4 ml of TRIzol was added and gently mixed by inversion for 1 min. Samples were

allowed to stand for 10 min at room temperature. To this solution, 0.25 ml of chloroform was added per 0.4 ml of TRIzol used. The contents were vortexed for 15 seconds. The tube was allowed to stand at room temperature for 5 mins. The resulting mixture was centrifuged at 12,000 rpm for 15 min at 4°C. The upper aqueous phase was collected in a new sterile microcentrifuge tube, to which 0.5 ml of isopropanol was added, gently mixed by inverting the contents for 30 seconds, and incubated at -20°C for 20 minutes. The contents were centrifuged at 12,000 rpm for 10 minutes at 4°C. The supernatant was discarded, and the RNA pellet was washed by adding 0.5 ml of 70% ethanol. The RNA mixture was centrifuged at 12,000 rpm at 4°C. The supernatant was carefully discarded, and the pellet was air-dried. The RNA pellet was then resuspended in 20 µl of diethyl polycarbonate (DEPC)-treated water. The total RNA yield (Table 1) was quantified using a Spectra Drop (SpectraMax i3x, Molecular Devices, USA).

Table 1: RT-qPCR analysis

NHDF cells Treatment	Test sample concentrations				
	0	1 pg/ ml	100 pg/ ml	1 ng/ ml	100 ng/ ml
RNA yield (ng/µl)	444.400	288.36	264.845	426.720	200.584

cDNA was synthesized from 500 ng of RNA using a cDNA synthesis kit from the Prime Script RT Reagent Kit (TAKARA) with oligo dT primers according to the manufacturer's instructions. The reaction volume was 20 µl, and cDNA synthesis was performed at 50°C for 30 min, followed by RT inactivation at 85°C for 5 min using the applied biosystem Veritii. The cDNA was further used for real-time PCR analysis.

cDNA SYNTHESIS

cDNA was synthesized from 2 µg of RNA using a PrimeScript cDNA synthesis kit (Takara) and oligo dT primers per the manufacturer's instructions. The reaction volume was 20 µL, and cDNA synthesis was performed on an Applied Biosystems instrument (Veritii). cDNA was used for qPCR (50°C for 30 min followed by 85°C for 5 min).

PRIMERS AND qPCR

The PCR mixture (final volume of 20 µL) contained 1 µL of cDNA, 10 µL of SYBR Green Master Mix, and one µM complementary forward and reverse primers specific for the respective target genes. The reaction conditions were as follows: initial denaturation at 95°C for 5 min, followed by 30 cycles of secondary denaturation at 95°C for 30 s, annealing at the optimized temperature for 30 s,

and extension at 72°C for 1 min. The number of cycles that allowed amplification in the exponential range without reaching a plateau was selected as the optimal number of cycles. The obtained results were analyzed using CFX Maestro software.

The fold change was calculated using the $\Delta\Delta CT$ method.

The comparative CT method was used to determine the relative expression of target genes to that of the housekeeping gene (β -actin) in untreated control cells.

The delta CT for each treatment was calculated using the following formula: $\Delta CT = Ct (\text{target gene}) - Ct (\text{reference gene})$.

To compare the delta Ct of individually treated samples with that of the untreated control samples, the Ct of each group was subtracted from that of the control to obtain the delta CT.

$\Delta\Delta CT = \Delta CT (\text{treatment group}) - \Delta CT (\text{control group})$.

The fold change in target gene expression for each treatment group was calculated using the following formula: $\text{Fold change} = 2^{-\Delta\Delta CT}$.

Results

Figure 1 shows the increased expression of all circadian transcription factors at a concentration of

100 ng of *metadichol*. *Bmal1* and *Per1* are maintained at normal levels, whereas *Ppargc1A*, *Cry1* and *Clock* exhibit increased expression.

Figure 1: Fold regulation of circadian transcription factors.




Table 2: Primer details

Primer	sequence Forward and reverse	Amplicon size	Annealing temperature
GAPDH	GTCTCTCTGACTTCAACAGCG	186	60
	ACCACCCTGTTGCTGTAGCCAA		
BMAL1	GCTCAGGAGAACCCAGGTTATC	160	59
	GCATCTGCTTCCAAGAGGCTCA		
CLOCK	CAGGCAGCATTTACCAGTCTATG	119	65
	GTAGCTTGAGACATCACTGGCTG		
PER	GCAGGCCAACCAGGAATACT	157	67
	CAGGAAGGAGACAGCCACTG		
CRY	GTGGACAACCGCCTCTAACTT	163	56
	TCCAGTGAAGGGACTCCATATT		
(PPARGC1A)	ACGCACCGAAATTCTCCCTT	172	56
	TCTGCCTCTCCCTTGCTTG		

The network formed by the transcription factors was generated using Pathway Studio ^{19,20,21} and is shown in Figure 2. The other key pathways and their impacts on diseases and organs are shown in Tables 3, 4, 5, and 6.

translational feedback loop in which the transcription factors *Clock* and *Bmal1* activate the expression of the genes *Cry1* and *Per1*, which encode proteins that inhibit the activity of *Clock-Bmal1*.^{22,23} Other transcription factors, such as *Ppargc1a* and *Bmal1*, modulate the expression of clock genes and metabolic genes.

The circadian clock genes form a transcriptional-

Figure 2: Network interactions of circadian genes.




Table 3: Top Pathways; Biological Processes.

Several key biological processes are related to circadian rhythm and processes involving sirtuins In aging (highlighted).

Name	Parent Folder	# of Entities	Expanded # of Entities	Overlap	Percent Overlap	Overlapping Entities	p value
Circadian Clock Genes Mutations Cause Insomnia	Aging Related Diseases; Sleep Dysregulation; Sleep Dysregulation (Neurological Diseases); nerve tissue; nervous system	26	41	4	9	CRY1, CLOCK, PER1, ARNTL	6.34966E-10
Circadian Clock and Sleep Regulation by Melatonin	Amino Acid Derived Hormones; Sleep Regulation; Sleep Regulation (Biological Process); nerve tissue; nervous system	26	41	4	9	CRY1, CLOCK, PER1, ARNTL	6.34966E-10
Circadian Clock in Sleep Regulation	Sleep Regulation; Sleep Regulation (Biological Process); nerve tissue; nervous system	32	55	4	7	CLOCK, CRY1, PER1, ARNTL	2.13638E-09
Circadian Clock Genes in Suprachiasmatic Nuclei Neurons	Sleep Regulation; Sleep Regulation (Biological Process); nerve tissue; nervous system; nucleus	64	125	4	3	CLOCK, CRY1, ARNTL, PER1	6.04168E-08
SIRT1 Signaling in Aging	Genomic Instability Associated with Aging; Genomic Instability Associated with Aging (Aging Biology); generic; generic; nucleus	64	170	3	1	CLOCK, ARNTL, PPARGC1A	2.90853E-05
SIRT4 Signaling in Aging	Genomic Instability Associated with Aging; Genomic Instability Associated with Aging	26	31	1	3	PPARGC1A	1.31176E-02

Name	Parent Folder	# of Entities	Expanded # of Entities	Overlap	Percent Overlap	Overlapping Entities	p value
	(Aging Biology); generic; generic; nucleus						
Vitamin D Activates Transcription	Vitamins Biology; Vitamins Biology (Biological Process); generic; generic	16	55	1	1	CLOCK	2.31784E-02
Agomelatine Antidepressant Action	Sleep Regulation; Sleep Regulation (Biological Process); nerve tissue; nervous system	26	85	1	1	PER1	3.56387E-02
SIRT7 Signaling in Aging	Genomic Instability Associated with Aging; Genomic Instability Associated with Aging (Aging Biology); generic; generic; nucleus	27	98	1	1	PPARGC1A	4.09986E-02
TGFB- COX2	Corneal stroma remodeling	47	115	1	0	PPARGC1A	4.79716E-02

Table 4. Organs that express molecules enriched in the input gene set

Highlights the presence of circadian genes in all key organs, such as the testis, brain, liver, lung nerve and kidney, that are necessary for human survival, with a P value of zero (highlighted)

Protein entities related to testis	10374	testis	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein entities related to cerebral cortex	8874	cerebral cortex	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein entities related to brain	11768	brain	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein entities related to neuron	9335	neuron	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein entities related to lung	10040	lung	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein entities related to kidney	10904	kidney	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein entities related to liver	9996	liver	4	0	ARNTL, CRY1, PER1, CLOCK	0.00000E+00
Protein entities related to GT1-7	277	GT1-7	5	1	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	3.37236E-08

Protein entities related to hypophysis pars tuberalis	111	hypophysis pars tuberalis	4	3	ARNTL, CRY1, PER1, CLOCK	1.30955E-07
Protein entities related to suprachiasmatic nucleus neuron	154	suprachiasmatic nucleus neuron	4	2	ARNTL, CRY1, PER1, CLOCK	4.90711E-07

Table 5 Diseases regulated by input genes

Most chronic disease impacts lead to aging and cancer, which are regulated by circadian genes.

Name	Total # of Neighbors	Gene Set Seed	Overlap	Percent Overlap	Overlapping Entities	p value
Protein regulators of glucose intolerance	1111	glucose intolerance	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	1.97088E-07
Protein regulators of elevated blood pressure	430	elevated blood pressure	4	0	ARNTL, PPARGC1A, CRY1, CLOCK	4.74904E-07
Protein regulators of hyperglycemia	1325	hyperglycemia	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	4.76213E-07
Protein regulators of circadian rhythm sleep disorder	6	circadian rhythm sleep disorder	2	28	CRY1, CLOCK	5.06905E-07
Protein regulators of intermittent hypoxia	142	intermittent hypoxia	3	2	ARNTL, CRY1, PER1	1.93132E-06
Protein regulators of seasonal affective disorder	14	seasonal affective disorder	2	13	ARNTL, CLOCK	3.07320E-06
Protein regulators of astrogliosis	731	astrogliosis	4	0	ARNTL, PPARGC1A, CRY1, CLOCK	3.94934E-06
Protein regulators of disorder of initiating and maintaining sleep	18	disorder of initiating and maintaining sleep	2	10	PPARGC1A, CLOCK	5.16533E-06
Protein regulators of sarcopenia	213	sarcopenia	3	1	ARNTL, PPARGC1A, CLOCK	6.53589E-06
Protein regulators of premature aging	221	premature aging	3	1	ARNTL, PPARGC1A, CLOCK	7.30046E-06

Table 6: Regulated cell processes

Key process involved is the regulation of apoptosis, cell proliferation and epigenetic modifications which is very important in cancer (highlighted)

Name	Total # of Neighbors	Overlap	Percent Overlap	Overlapping Entities	p value
Protein regulators of anagen	273	4	1	ARNTL, CRY1, PER1, CLOCK	8.49703E-07
Protein regulators of apoptosis	13703	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein regulators of biological rhythm	108	5	4	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	3.19377E-11
Protein regulators of cell proliferation	15725	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	0.00000E+00
Protein regulators of circadian behavior	103	4	3	ARNTL, CRY1, PER1, CLOCK	1.67667E-08
Protein regulators of epigenetic modification	641	5	0	ARNTL, PPARGC1A, CRY1, PER1, CLOCK	2.54371E-07
Protein regulators of light dark cycle	89	4	4	ARNTL, PPARGC1A, CRY1, PER1	9.26714E-09
Protein regulators of lipid absorption	212	4	1	ARNTL, PPARGC1A, PER1, CLOCK	3.08178E-07
Protein regulators of locomotor rhythm	105	4	3	ARNTL, CRY1, PER1, CLOCK	1.81257E-08
Protein regulators of sleep waking cycle	155	4	2	ARNTL, CRY1, PER1, CLOCK	8.74397E-08

Discussion.

The interactions and roles of *Clock*, *Cry1*, *Per1*, *Bmal1*, and *Ppargc1a* in regulating circadian rhythm are summarized below.

Clock and *Bmal1* form a heterodimer that activates the transcription of other clock genes, including *Per1* and *Cry1*. This activation occurs by binding to E-box promoter elements in the genome, thus activating many clock-controlled genes. ²⁴ This activation leads to the production of *Per* and *Cry* proteins, which accumulate and form complexes that repress their own transcription by binding to the *Clock:Bmal1* complex, creating a negative feedback loop. This cycle repeats approximately every 24 hours, contributing to the circadian rhythm. ²⁵⁻²⁷

Per1 and *Cry1* form a complex that inhibits the activity of *Clock-Bmal1*, creating a negative feedback loop. This inhibition leads to the suppression of their own transcription, thus forming the negative arm of the circadian clock. ²⁸ *Per1*, along with other *Per* and *Cry* proteins, is involved in the regulation of the expression of genes outside of the core clock genes. *Per1* and *Cry1/2* may regulate the expression of genes outside of the core clock, indicating a broader role in cellular function. ²⁹

The expression levels of *Per1* and *Bmal1* are maintained through a complex interplay of transcriptional, posttranscriptional, and posttranslational modifications. Disruptions in the circadian rhythms of *Per1* and *Bmal1* have been linked to various physiological and pathological conditions. For instance, circadian misalignment and disruptions in circadian rhythms have been

associated with an increased risk of various diseases, including cancer. ³⁰⁻³³ Concentration 100 ng/ml of Metadichol maintains normal levels of *Per1* and *Bmal1*. This is crucial for the proper functioning of the circadian rhythm, and disruptions in circadian rhythm expression can have significant implications for human health.

Ppargc1a is a transcriptional coactivator that plays a critical role in the maintenance of energy metabolism. Pgc-1alpha has been found to interact with a gene regulatory network of the circadian clock. ³⁴ Pgc-1alpha stimulates the expression of clock genes, notably *Bmal1* (*Arntl*) and *Rev-Erb alpha* (*Nr1d1*), through coactivation of the ROR family of orphan nuclear receptors. ³⁵ *Ppargc1a*, *Bmal1*, and *Clock* are interconnected in regulating circadian rhythm and metabolic processes. *Bmal1* and *Clock* have been predicted to be significant upstream regulators, and they function as a heterodimer (*Bmal1:Clock*) that binds the enhancer box (E-box) regulatory element, regulating the transcription of the Period (*Per*) and Cryptochrome (*Cry*) genes, which form the negative arm of the circadian clock.

It is highly unlikely that metadichol can directly activate these transcription factors. This happens through upstream genes. Previously, we showed that metadichol is expressed on all 48 nuclei. Table 7 shows the fold changes in nuclear receptor levels induced by metadichol in fibroblasts. ³⁶ Table 7 shows the fold increases in the levels of the nuclear receptors *RXR*, *RORα*, *NR1F1*, *NR1D1* (*REV-ErBα*) and *HNF4A* in fibroblasts. The highest expression occurred between 1 picogram and 1 nanogram per ml.

Table 7: Metadichol Nuclear receptor Fold increase in Fibroblasts

Common Names	IUPAC Name	1 pg	100 pg	1 ng	100 ng
<u>Rev-ErbAα</u>	NR1D1	1.5	0.64	0.07	0.75
<u>RORα</u>	NR1F1	0.9	1.14	1.33	1.01
HNF4A	NR2A1	6.03	3.4	2.69	3.64
RXRA	NR2B1	2.5	0.86	1.32	0.98
RXRB	NR2B2	2.68	1.3	1.18	1.1
RXRG	NR2B3	2.84	2.95	3.9	1.09
PPARG	NR1C3	3.76	6.11	7.31	3.07

The expression of the *Clock* gene is regulated ³⁷ by the nuclear receptor *RORα* (retinoic acid receptor-related orphan receptor alpha) and transcriptional coregulator receptor interacting protein 140 (RIP140).

RORα is involved in a secondary feedback loop that regulates the *Clock* gene, and RIP140 has been identified as a modulator of *Clock*, participating in a feedback mechanism affecting the circadian clock.

Additionally, the nuclear receptor *NR1D1* (nuclear receptor subfamily 1 group D member 1) is involved in regulating the expression of target genes, including the *Clock* gene. *RORα* and *NR1D1* play roles in the expression of the *Clock* gene. ³⁸

The nuclear receptor responsible for the expression of the *Cry1* gene is *HNF4A*. ³⁹ *HNF4A* (*NR2A1*) is critical for

circadian rhythm maintenance and period regulation in liver and colon cells. It acts differently from other *Clock:Bmal1* repressors and binds to *Cry* proteins, thereby inhibiting *Clock:Bmal1* via a mechanism independent of *Cry1*. On the other hand, the nuclear receptor *REV-ERB α* , also known as *NR1D1*, is involved in the regulation of the *Bmal1* gene, which is part of the core circadian clock. Although *REV-ERB α* regulates the expression of *Bmal1*, it does not directly regulate the expression of the *Cry1* gene.⁴¹ *HNF4A* is likely the nuclear receptor responsible for the expression of the *Cry1* gene.

The nuclear receptor responsible for the expression of the *BMAL1* gene is retinoid-related orphan receptor α (*ROR α*), also known as *NR1F1*. *ROR α* stimulates transcription through the *BMAL1* promoter, thereby regulating the expression of the *BMAL1* gene.⁴² This regulation is part of the complex network of interactions involved in the circadian clock, where *ROR α* plays a key role in activating the transcription of clock genes, including *Bmal1*. Therefore, *ROR α* is the nuclear receptor responsible for the expression of the *Bmal1* gene.

The nuclear receptors responsible for the expression of the *Ppargc1 α* (*PGC-1 α*) gene are the retinoid X receptor (*RXR*) and peroxisome proliferator-activated receptor gamma (*Ppar- γ*). *Pgc-1 α* binds to *Ppar- γ* and coactivates *Ppar- γ* to stimulate the transcription of genes involved in various metabolic processes, including mitochondrial biogenesis and energy metabolism.⁴³ The interaction between *Pgc-1 α* and *Ppar γ* is essential for regulating genes related to energy metabolism and other physiological functions. Therefore, *Ppar γ* and its coactivator *PGC-1 α* are crucial for regulating various metabolic pathways. Thus, the effect of metadichol on nuclear receptor³⁶ leads to the regulation of circadian gene expression.

Metadichol also induces the expression of *Sirtuin 1* and *6* in fibroblasts.⁴⁴ The fold increases are shown in Table 8. Sirtuins are a family of NAD⁺-dependent protein deacetylases that play a crucial role in various cellular processes, including aging, metabolism, and the regulation of circadian rhythms. Sirtuins, particularly *Sirt1*, have been shown to interact with components of the circadian clock machinery directly, influencing the regulation of circadian rhythms.⁴⁵

Table 8: Metadichol and *Sirt1* and *Sirt6*-fold expression

Gene	1 pg	100 pg	1 ng	100 ng	Control
Sirt1	3.29	2.30	3.48	6.92	1.00
Sirt6	2.19	1.97	3.01	4.26	1.00

While *Sirt1* is the most studied sirtuin in the context of circadian rhythms, other members of the sirtuin family also contribute to circadian regulation. *Sirt6* has been identified as a critical regulator of circadian transcription, suggesting that it also serves as an interface between the circadian clock and cellular metabolism.⁴⁶

Sirt6 may also interact with *Pgc-1 α* , a coactivator that regulates genes involved in energy metabolism.⁴⁷ This interaction is important for maintaining metabolic balance, which is often disrupted in cancer cells.^{48,49}

The involvement of sirtuins in circadian regulation has significant implications for understanding the pathophysiology of various diseases, including metabolic disorders, aging-related diseases, and cancer. Disruptions in circadian rhythms have been linked to a range of health issues, and the role of sirtuins in this process highlights their potential as therapeutic targets.⁵⁰⁻⁶³

Sirt1 and *Sirt6* play a critical role in regulating circadian rhythms through their interactions with core clock components and modulation of metabolic processes. Their activity influences the stability and

function of circadian proteins, aligning physiological processes with the environmental day–night cycle. This intricate relationship between sirtuins and the circadian clock underscores the importance of these proteins in maintaining cellular and organismal homeostasis.

Conclusions

Our findings show that metadichol, a small molecule, induces the expression of transcription factors such as *Clock*, *Cry1*, *Per1*, *Bmal1*, *Ppardc1 α* , and *Arntl* is significant for several reasons. These genes have important role in and could be of therapeutic use in hypertension, insulin resistance aging and cancer.

Metadichol has been shown to regulate the expression of genes implicated in viral infections⁶⁴ and by blocking the entry of SARS-CoV-2 into host cells, indicating a potential function in antiviral responses. It also expresses Yamanaka factors⁶⁵ in a variety of cell types which can lead to potential applications in stem cell therapy and regenerative medicine. Metadichol is nontoxic⁶⁶⁻⁶⁸ and has been commercially accessible for a decade. Metadichol proven ability to regulate the expression multitude of transcription factors like Sirtuins, toll receptors

can potentially lead to a wide range of applications in cancer, neurology, chronic disorders, infectious diseases, and regenerative medicine.

Conflict of interest

The author is the founder and CEO of Nanorx, Inc., a privately held company.

Published as a Preprint; P.R. Raghavan, Metadichol® induced expression of circadian clock transcription factors in human fibroblasts. bioRxiv 2024.02.21.581403;

Doi:

<https://doi.org/10.1101/2024.02.21.581403>

Supplementary Materials. Raw data: qRT-PCR.

References

1. Circadian Rhythms; <https://www.nigms.nih.gov/education/fact-sheets/Pages/circadian-rhythms.aspx>
2. Physiology; Circadian rhythms. <https://www.ncbi.nlm.nih.gov/books/NBK519507/>
3. Rijo-Ferreira, F., Takahashi, J.S. Genomics of circadian rhythms in health and disease. *Genome Med*, 2019; 11, 82 <https://doi.org/10.1186/s13073-019-0704-0>.
4. Trott AJ, Menet JS. Regulation of circadian clock transcriptional output by CLOCK:BMAL1. *PLoS Genet*. 2018; Jan 4;14(1):e1007156. Doi: 10.1371/journal.pgen.1007156.
5. Alex A Koch ,et al. 2022. Quantification of protein abundance and interaction defines a mechanism for operation of the circadian clock *eLife* 11:e73976. <https://doi.org/10.7554/eLife.73976>.
6. Kawai M, Rosen CJ. PPAR γ : a circadian transcription factor in adipogenesis and osteogenesis. *Nat Rev Endocrinol*. 2010 ;Nov;6(11):629-36. Doi: 10.1038/nrendo.2010.155.
7. Liu H, Liu Y, Hai R, Liao W, Luo X. The role of circadian clocks in cancer: Mechanisms and clinical implications. *Genes Dis*. 2022; May 28;10(4):1279-1290. Doi: 10.1016/j.gendis.2022.05.014.
8. Zhang W, Xiong Y, Tao R, Panayi AC, Mi B, Liu G. Emerging Insight into the Role of Circadian Clock Gene BMAL1 in Cellular Senescence. *Front Endocrinol (Lausanne)*. 2022; Jun 6;13:915139. Doi: 10.3389/fendo.2022.915139.
9. Yanling Xie *Front. Physiol.*, 2019; New Insights into the Circadian Rhythm and Its Related Diseases Sec. Chronobiology Volume 10. | <https://doi.org/10.3389/fphys.2019.00682>.
10. Walker, W.H., Walton, J.C., DeVries, A.C. et al. Circadian rhythm disruption and mental health. *Transl Psychiatry*, 2020; 10, 28. <https://doi.org/10.1038/s41398-020-0694-0>.
11. A Zhang W, Xiong Y, Tao R, Panayi AC, Mi B, Liu G. Emerging Insight into the Role of Circadian Clock Gene BMAL1 in Cellular Senescence. *Front Endocrinol (Lausanne)*. 2022; Jun 6;13:915139. Doi: 10.3389/fendo.2022.915139.
12. Vadnie CA, McClung CA. Circadian Rhythm Disturbances in Mood Disorders: Insights into the Role of the Suprachiasmatic Nucleus. *Neural Plast*. 2017;1504507. Doi: 10.1155/2017/1504507.
13. Oike H, Kobori M .Resveratrol regulates circadian clock genes in Rat-1 fibroblasts. *Biosci Biotechnol Biochem*, 72008; 2(11):3038-40. Doi: 10.1271/bbb.80426. Epub 2008.
14. Richards J,et al. Opposing actions of Per1 and Cry2 in the regulation of Per1 target gene expression in the liver and kidney. *Am J Physiol Regul Integr Comp Physiol*, 2013; 305(7):R735-47. Doi: 10.1152/ajpregu.00195.2013. Epub 2013 Jul 3.; Bellfy, L., Smies, C.W., Bernhardt, A.R. et al. The clock gene *Per1* may exert diurnal control over hippocampal memory consolidation. *Neuropsychopharmacol*. 2023; 48, 1789–1797. <https://doi.org/10.1038/s41386-023-01616-1>
15. Gao R, et al. Cryptochrome 1 activation inhibits melanogenesis and melanosome transport through negative regulation of cAMP/PKA/CREB signaling pathway. *Front Pharmacol*, 2023; 6;14:1081030. Doi: 10.3389/fphar.2023.1081030
16. Dierickx P, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. *Proc Natl Acad Sci U S A*,2019;18;116(25):12147-12152. Doi: 10.1073/pnas.1904226116.
17. Raghavan PR. US Patents: 8,722,093 (2014); 9,034,383 (2015); 9,006,292; 2015.
18. Innovation Intelligence. <https://www.elsevier.com/solutions/data-analytics>.
19. Sivachenko, A. Y., Yuryev, A., Daraselia, N. & Mazo, I. Molecular networks in microarray analysis. *J. Bioinform. Comput. Biol*. 2007; 5, 429–456.
20. Nikitin, A., et al 2007. Pathway studio--the analysis and navigation of molecular networks. *Bioinformatics* 2003; 19, 2155–2157.
21. Tomczak, A. et al. Interpretation of biological experiments changes with evolution of the gene ontology and its annotations. *Sci. Rep.*20018; 8, 5115.
22. Zheng, Y. et al . Neural function of Bmal1: an overview. *Cell Biosci* 2023; 13, 1. <https://doi.org/10.1186/s13578-022-00947-8>
23. Cao X, et al Molecular mechanism of the repressive phase of the mammalian circadian clock. *Proc Natl Acad Sci USA*, 12;118(2):e2021174118. Doi: 10.1073/pnas.2021174118.
24. MarcheVA B, et al. Circadian clocks and metabolism. *Handb Exp Pharmacol*.2013; 217:127-55. Doi: 10.1007/978-3-642-25950-0_6. PMID: 23604478; PMCID: PMC4089089
25. Haque SN, et al. Effects of BMAL1 Manipulation on the Brain's Master Circadian Clock and Behavior. *Yale J Biol Med*. 2019; 27;92(2):251-258.
26. Takahashi JS . Transcriptional architecture of the mammalian circadian clock. *Nat Rev Genet*. 2017; 18(3):164-179. Doi: 10.1038/nrg.2016.150. Epub 2016 Dec 19

27. Trott AJ, Menet JS. Regulation of circadian clock transcriptional output by CLOCK: BMAL1. *PLoS Genet* 2018;14(1): e1007156. <https://doi.org/10.1371/journal.pgen.1007156>.
28. Cox KH, Takahashi JS. Circadian clock genes and the transcriptional architecture of the clock mechanism. *J Mol Endocrinol.* 2019; Nov;63(4): R93-R102. Doi: 10.1530/JME-19-0153.
29. Fagiani, F., Di Marino, D., Romagnoli, A. et al. Molecular regulations of circadian rhythm and implications for physiology and diseases. *Sig Transduct Target Ther* 2022; 7, 41. <https://doi.org/10.1038/s41392-022-00899-y>
30. Rijo-Ferreira, F., Takahashi, J.S. Genomics of circadian rhythms in health and disease. *Genome Med*, 2019; 11, 82 . <https://doi.org/10.1186/s13073-019-0704-0>.
31. Abe, Y.O. et al. Rhythmic transcription of *Bmal1* stabilizes the circadian timekeeping system in mammals. *Nat Commun*, 2022; 13, 4652. <https://doi.org/10.1038/s41467-022-32326-9>
32. Trott AJ, Menet JS. Regulation of circadian clock transcriptional output by CLOCK: BMAL1. *PLoS Genet* 2022; 14(1): e1007156. <https://doi.org/10.1371/journal.pgen.1007156>.
33. Han, et al. Role of Circadian Rhythm and Impact of Circadian Rhythm Disturbance on the Metabolism and Disease. *Journal of Cardiovascular Pharmacology*, 2022; 79(3):p 254-263. Doi: 10.1097/FJC.0000000000001178.
34. Liu C, et al. Transcriptional coactivator PGC-1 alpha integrates the mammalian clock and energy metabolism. *Nature*. 2007; 447(7143):477-81. Doi: 10.1038/nature05767).
35. Ray DW. Circadian Rhythm and Nuclear Receptors, *Adv Exp Med Biol*, 2022; 1390:143-153. Doi: 10.1007/978-3-031-11836-4_8.
36. Palayakotai R, Raghavan. Metadichol® A Nano Lipid Emulsion that Expresses All 49 Nuclear Receptors in Stem and Somatic Cells. *Archives of Clinical and Biomedical Research*. 2023; 7: 524-536. DOI:10.26502/acbr.50170368.
37. Poliandri AH, et al. Modulation of clock gene expression by the transcriptional coregulator receptor interacting protein 140 (RIP140). *J Biol Rhythms*. 2011; (3):187-99. Doi: 10.1177/0748730411401579.
38. Crumbley C, Burris TP. Direct regulation of CLOCK expression by REV-ERB. *PLoS One*. 2011; 29;6(3):e17290. Doi: 10.1371/journal.pone.0017290.
39. Qu M, et al . Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-specific circadian networks. *Proc Natl Acad Sci U S A*, 2018; 115(52):E12305-E12312. Doi: 10.1073/pnas.1816411115.
40. Casey T, et al. Core circadian clock transcription factor BMAL1 regulates mammary epithelial cell growth, differentiation, and milk component synthesis. *PLoS One*, 2021; 6(8):e0248199.
41. Yang X. A wheel of time. The circadian clock, nuclear receptors, and physiology. *Genes Dev* 2010; 15;24(8):741-7. Doi: 10.1101/gad.1920710.
42. Akashi M, Takumi T. The orphan nuclear receptor ROR alpha regulates circadian transcription of the mammalian core-clock *Bmal1*. *Nat Struct Mol Biol.* 2—5; 12(5):441-8. Doi: 10.1038/nsmb925.
43. Liang H, Ward WF. PGC-1 alpha: a key regulator of energy metabolism. *Adv Physiol Educ.* 2006; Dec;30(4):145-51. Doi: 10.1152/advan.00052.2006.
44. Raghavan.P.R Metadichol a Sirtuin Modulator for Anti-Aging Therapies This is a preprint; .<https://doi.org/10.21203/rs.3.rs-3199226/v2>.
45. Masri S, Sassone-Corsi P. Sirtuins and the circadian clock: bridging chromatin and metabolism. *Sci Signal*, 2014; 7(342):re6. Doi: 10.1126/scisignal.2005685.
46. Sun S, et al 2019. Sirt6 deacetylase activity regulates circadian rhythms via Per2. *Biochem Biophys Res Commun*, 2019; 511(2):234-238. Doi: 10.1016/j.bbrc.2019.01.143.
47. Becherini, P., Caffa, I., Piacente, F. et al. SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice. *Cancer Metab*, 2021; 9, 6. <https://doi.org/10.1186/s40170-021-00240-1>.
48. Desantis V, Lamanuzzi A, Vacca A. The role of SIRT6 in tumors. *Hematologica.* 2018; Jan;103(1):1-4. Doi: 10.3324/hematol.2017.182675.
49. Raghu S, Prabhashankar AB, Shivanaiah B, Tripathi E, Sundaresan NR. Sirtuin 6 Is a Critical Epigenetic Regulator of Cancer. *Subcell Biochem.* 2022;100:337-360. Doi: 10.1007/978-3-031-07634-3_10.
50. Soni, S.K., Basu, P., Singaravel, M. et al. Sirtuins and the circadian clock interplay in cardioprotection: focus on sirtuin 1. *Cell. Mol. Life Sci.* 2021;78, 2503–2515. <https://doi.org/10.1007/s00018-020-03713-6>
51. Bellet MM, et al. Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. *Proc Natl Acad Sci U S A*, 2013; 110(9):3333-8. Doi: 10.1073/pnas.1214266110

52. Zhou S, et al. Circadian Clock and Sirtuins in Diabetic Lung: A Mechanistic Perspective. *Front Endocrinol (Lausanne)*, 2020; 1:173. Doi: 10.3389/fendo.2020.00173.
53. Jung-Hynes et al. *J Pineal Res*, 2010; 48(1):9-19. Doi: 10.1111/j.1600-079X.2009.00729.x.
54. Ribeiro, R.F.N et al 2022. . SIRT1 activation and its circadian clock control: a promising approach against frailty in neurodegenerative disorders. *Aging Clin Exp Res*, 2016; 34, 2963–2976 . <https://doi.org/10.1007/s40520-022-02257-y>.
55. Wang, RH et al. Negative reciprocal regulation between Sirt1 and Per2 modulates the circadian clock and aging. *Sci Rep*, 2016; 6, 28633. <https://doi.org/10.1038/srep28633>.
56. Chandramowlishwaran P. Role of Sirtuins in Modulating Neurodegeneration of the Enteric Nervous System and Central Nervous System. *Front Neurosci*. 2020;14:614331. Doi: 10.3389/fnins.2020.614331.
57. Chang HC, Guarente L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. *Cell*, 2013; 153(7):1448-60. Doi: 10.1016/j.cell.2013.05.027.
58. Masri S . Sirtuin-dependent clock control: new advances in metabolism, aging and cancer. *Curr Opin Clin Nutr Metab Care*. 2015; 18(6):521-7. Doi: 10.1097/MCO.0000000000000219.
59. Fagiani, F. et al. Molecular regulations of circadian rhythm and implications for physiology and diseases. *Sig Transduct Target Ther*, 2022; r 7, 4. <https://doi.org/10.1038/s41392-022-00899-y>
60. Soni, S.K., et al. Sirtuins and the circadian clock interplay in cardioprotection: focus on sirtuin 1. *Cell. Mol. Life Sci*. 2021; 78, 2503–2515. <https://doi.org/10.1007/s00018-020-03713-6>
61. Bellet MM, et al. Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. *Proc Natl Acad Sci U S A*, 2013; 26;110(9):3333-8. Doi: 10.1073/pnas.1214266110
62. Zhou S, et al. Circadian Clock and Sirtuins in Diabetic Lung: A Mechanistic Perspective. *Front Endocrinol (Lausanne)*, 2020; 3;11:173. Doi: 10.3389/fendo.2020.00173.
63. Jung-Hynes B, et al. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. *J Pineal Res*. 2010; 48(1):9-19. Doi: 10.1111/j.1600-079X.2009.00729.x.
64. P R. Raghavan, "Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro", *BioMed Research International*, 2022; vol.2022, Article ID 1558860, 14 pages. <https://doi.org/10.1155/2022/1558860>
65. P.R. Raghavan. Metadichol is a natural ligand for expressing Yamanaka reprogramming factors in somatic and primary cancer cell lines *Preprint 2023*; <https://doi.org/10.21203/rs.3.rs-1727437/v4>.
66. C. Aleman, et al. A 12-month study of policosanol oral toxicity in Sprague Dawley rats," *Toxicology Letters*, 1994; vol. 70, no. 1, pp. 77–87.
67. C. L. Alemán, et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24-month study, Teratogenesis, Carcinogenesis, and Mutagenesis, 1994; vol. 14, no. 5, pp. 239–249,.
68. C. L. Alemán, et al. Carcinogenicity of policosanol in mice: an 18-month study," *Food and Chemical Toxicology*, 1995; vol. 33, no. 7, pp. 573–578.